Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt.
Learn more about our ongoing clinical trials for novel drugs targeting cancer stem cells »
ANNOUNCEMENTS 
May 14, 2013
Jack Green Joins Verastem as Chief Financial Officer
May 9, 2013
Verastem Reports First Quarter 2013 Financial and Corporate Results
May 8, 2013
Verastem to Present at Upcoming Conferences
Cancer Stem Cells
The majority of cancer drugs, while killing the bulk of tumor cells, ultimately fail to induce durable clinical responses. A reason for this failure may be the presence of a minority of cells in the tumor called cancer stem cells which are resistant to existing cancer therapies.
Using our proprietary technology we are identifying and developing drugs that target and kill cancer stem cells.
VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer